Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions

Area of Science:

• Immunology
• Virology
• Infectious Diseases

Background:

• Individuals with Human Immunodeficiency Virus type 1 (HIV-1) infection can develop cross-neutralizing antibodies.
• These antibodies target a broad range of primary HIV-1 isolates, including Group M (envA-H) and Group O.

Purpose of the Study:

• To investigate the neutralization kinetics of primary HIV-1 isolates using cross-neutralizing antibodies.
• To compare different neutralization assay conditions and their impact on antibody efficacy.

Main Methods:

• Comparison of various neutralization assay conditions, defined by antibody-virus pre-incubation time (a), virus-cell absorption time (b), and total culture period (c).
• Assays utilized peripheral blood mononuclear cells (PBMC) or GHOST indicator cells to measure viral antigen production or fluorescent cell counts.

Main Results:

• Neutralizing antibodies are detectable against diverse primary HIV-1 isolates in PBMC assays with short incubation periods (e.g., 1/2/7 or 1/24/7).
• Extended culture periods (e.g., 1/2/14 or 1/24/14) can lead to a loss of detectable neutralization.
• Neutralization can occur even without antibody-virus pre-incubation (a=0 hr), indicating activity post-viral binding.
• Neutralization of primary HIV-1 isolates by cross-reactive antibodies can continue after the virus has attached to the target cell.

Conclusions:

• Neutralization of primary HIV-1 isolates by cross-reactive antibodies is a dynamic process that can extend beyond initial viral attachment.
• This neutralization typically results in a reduction of viral replication rates, rather than a complete abrogation of infectivity.
• Assay conditions, particularly culture duration, significantly influence the detection and assessment of neutralization efficacy.